Supplementary Table S2: Characteristics of biopsies obtained on PancSeq protocol. \*Cellularity from FFPE core biopsy specimens. Cellularity data not available from patients who underwent fine needle aspirates (N=3).

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | Pilot Study(N=10) | CLIA-Certified Study(N=69) | Full Population(N=79) |
| Biopsy dates | Mar-Sept 15 | Oct 15-Jun 17 | Mar 15-Jun 17 |
| Biopsy site, N (%) |  |  |  |
|  Primary pancreatic tumor | 1 (10) | 6 (9) | 7 (9) |
|  Metastatic lesion |  |  |  |
|  Liver  | 8 (80) | 55 (80) | 63 (80) |
|  Peritoneum  | 1 (10) | 5 (7) | 6 (8) |
|  Lymph node  | 0 (0) | 2 (3) | 2 (3) |
|  Ovary | 0 (0) | 1 (1) | 1 (1) |
| Biopsy approach, N (%) |  |  |  |
|  Percutaneous  | 10 (100) | 62 (90) | 72 (91) |
|  Endoscopic  | 0 (0) | 6 (9) | 6 (8) |
|  Intraoperative | 0 (0) | 1 (1) | 1 (1) |
| Biopsy type, N (%) |  |  |  |
|  Fine needle aspirate (25-gauge) | 1 (10) | 2 (3) | 3 (4) |
|  Core needle biopsy (18 to 22-gauge) | 9 (90) | 67 (97) | 76 (96) |
| Specimens obtained per biopsy, Median (range) | 5 (3-8) | 5 (1-10) | 5 (1-10) |
| Size of lesion biopsied (cm), Median (range) | 2.0 (0.9 – 4.1) | 3.0 (0.7-7.6) | 2.9 (0.7-7.6) |
| Biopsy indication, N (%) |  |  |  |
|  Clinical indication  | 10 (100) | 44 (64) | 54 (68) |
|  Research purposes only | 0 (0) | 25 (36) | 25 (32) |
| Whole exome sequencing, N (%) | 10 (100) | 63 (91) | 73 (92) |
| Tissue preservation of sequenced core, N (%) |  |  |  |
|  Fresh frozen | 10 (100) | 58 (92) | 68 (93) |
|  Formalin-fix, paraffin-embedded (FFPE) | 0 (0) | 5 (8)  | 5 (7) |
| Tumor cellularity by H&E, Median (range) \* | 40 (20-70) | 40 (5-80) | 40 (5-80) |
| WES data with successful mutation and copy number calls, N (%) | 8 (80) | 63 (100) | 71 (97) |
| Mean target coverage, Median (range) |  |  |  |
|  Normal specimen | 117 (90-179) | 178 (139-301) | 176 (90-301) |
|  Tumor specimen | 285 (157-626) | 191 (153-283) | 191 (153-626) |
| ABSOLUTE tumor cellularity, Median (range) | 0.36 (0.15-0.91) | 0.33 (0.03-0.76) | 0.33 (0.03-0.91) |
| Days from biopsy to analyzed data, Median (range) |  |  |  |
|  Clinical indication | - | 39 (16-67) |  |
|  Research purposes only | - | 28 (15-51) |  |
| RNAseq, N (%) | 9 (90) | 54 (78) | 63 (80) |
|  Read count, Median (range) | 1.0E+08(6.9E+07-2.2E+08) | 9.1E+07 (2.5E+04-1.7E+08) | 9.2E+07(2.5E+04-2.2E+08) |